By correcting for ancestral bias in publicly available datasets, PhyloFrame produces better outcomes predictions for under-sampled populations.

Coeptis previously held limited co-development rights to GEAR. In conjunction with the new license agreement, Coeptis has formed a majority-owned subsidiary, called GEAR Therapeutics, to evaluate GEAR ...

The Rome-based charity recently applied for marketing authorization of the same gene therapy, previously advanced by Orchard Therapeutics, in the EU.

Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.

NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...

ElevateBio has entered into a multi-year collaboration with Amazon's cloud arm to identify treatment targets and new CRISPR systems.

NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial.

The firm will use the proceeds to advance its platform technology, R&D, and pre-commercialization activities for its base-editing drugs.

NEW YORK – Tethis on Monday said it has partnered with Sheba Medical Center in Israel to evaluate its artificial intelligence-driven technology in a clinical study, in which they plan to measure ...